Midatech Pharma Plc (Form: 6-K, Received: 06/21/2022 16:46:37)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of June 2022

Commission File Number 001-37652

Midatech Pharma PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-233901).

Appointment of New Chairman of the Board

As previously disclosed, on June 20, 2022, Rolf Stahel resigned as Chairman of Midatech Pharma PLC (the “Company”). Mr. Stahel resignation was not the result of any disagreements with the Company.

Further, as previously disclosed, on June 20, 2022, the Board of Directors of the Company (the “Board”) appointed Dr. Stephen Parker as a director and Chairman of the Board. A copy of the press release announcing the appointment is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Dr. Parker, aged 63, has a career in the healthcare and pharma sector that spans over 30 years, including 10 years in advisory roles. Dr. Parker has served as Managing Director of sp2 Consulting Limited since 2002, as well as an advisor to Opus Corporate Finance LLP since 2019. Dr. Parker has also served as Chairman of Sareum Holdings plc (AIM: SAR) since May 2016 and Drishti Discoveries Limited since January 2021, as Senior Independent Director of MGC Pharmaceuticals Limited (ASX, LSE:MXC) since March 2019, and as a director of Eternans Limited since July 2019 and sp2 Asset Management Limited since September 2018. Previously, Dr. Parker served as a director of Albucasis Limited from September 2013 to September 2019, as Chairman of Liverpool Chirochem Limited from July 2017 to July 2018, and as a director and Chairman of Silence Therapeutics plc (LSE: SLN) from November 2013 to April 2019. Dr. Parker also has corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings Brothers Limited, SBC Warburg Dillon Read, and Apax Partners LLP, and previously served as a director at subsidiaries of Celtic Pharma GP Limited and Chief Financial Officer of Oxford GlycoSciences. Dr. Parker received his D.Phil in Biochemistry from the University of Oxford, MBA in Business Administration from City University, London, and B.Sc. in Chemical Sciences from the University of East Anglia.

In connection with Dr. Parker’s appointment, Dr. Parker and the Company entered into a terms of appointment agreement (the “Agreement”). The initial term of appointment for Dr. Parker expires on June 19, 2023. Pursuant to the terms of the Agreement, Dr. Parker is to be paid an annual fee for services as a director of £82,000, and is entitled to additional payments depending upon the amount of time he devotes to the Company under the Agreement. In addition, in connection with the execution of the Agreement, the Company expects to grant to Dr. Parker options to acquire the Company’s ordinary shares with an aggregate exercise price of £42,000. The foregoing description of the Agreement is qualified in its entirety by reference to the full text of such Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

There are no arrangements or understandings between Dr. Parker and any other person pursuant to which he was appointed as a director of the Company.

Results of 2022 Annual General Meeting

On June 20, 2022, the Company issued a press releasing announcing the results of its 2022 Annual General Meeting. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

SUBMITTED HEREWITH

Attached to the Registrant’s Form 6-K filing for the month of June 2022, and incorporated by reference herein, is:

Exhibit No.		Description

10.1		Terms of Appointment, dated as of June 20, 2022, by and between Midatech Pharma PLC and Stephen Parker.
99.1		Press Release, dated June 20, 2022, entitled “Directorate Change.”
99.2		Press release, dated June 20, 2022, entitled “Result of 2022 Annual General Meeting.”
99.3		Press release, dated June 21, 2022, entitled “Orphan Designation Granted by EMA to MTX110 Development for Treatment of Glioma.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Midatech Pharma PLC

Date: June 21, 2022	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer and Chief Financial Officer

Exhibit 10.1

DATED: 20^th JUNE 2022

TERMS OF APPOINTMENT

DIRECTOR

(By way of Deed)

Between:

(1) MIDATECH PHARMA PLC

and

(2) STEPHEN BARRY PARKER

This Agreement is dated the 20^th day of JUNE 2022

BETWEEN:

(1)

MIDATECH PHARMA PLC a company registered in England under number 09216368 whose address is at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ, UK (the “Company”); and

(2)

STEPHEN BARRY PARKER (“You/you”).

TERMS OF APPOINTMENT

1.1

You agree to your appointment as a non-executive director of the Company and as Chairman of the Board (as defined below) and the Company agrees to your appointment on the terms and conditions of appointment set out in this agreement. You agree to chair or serve on such other committees of the Company as the Board may determine from time to time and acknowledge that no additional fees will be due to you for performing such additional duties.

1.2

Your appointment as a non-executive director under this agreement commenced on 20 June 2022. Subject to the terms of this agreement, your appointment shall be for an initial fixed term of twelve (12) months and will terminate on 19^th June 2023 without the need for notice (“the Initial Fixed Term”). Any continuance of your appointment after the Initial Fixed Term will be subject to re-election by the directors of the Company on an annual basis. Your appointment as a non-executive director may be terminated earlier:

1.2.1

by either party to this agreement giving to the other party not less than three (3) months’ written notice expiring on or after the end of the Initial Fixed Term;

1.2.2

at any time in accordance with clause 9 of this agreement; or

1.2.3

at any time in accordance with clause 14 of this agreement; or

1.2.4

if, after the expiry of the Initial Fixed Term, you fail to be re-elected as a non-executive director by the directors of the Company.

1.3

You agree that you have no right to be appointed to or to remain a member or the chairman of any particular committee of the Board (including, but not limited to, the Audit Committee, the Remuneration Committee and the Nomination Committee) and that your removal from any such committee to which you are appointed shall not constitute a breach of this agreement.

1.4

You shall, unless prevented by sickness or ill-health and subject always to clause 1.5, properly perform such duties as are appropriate to your role as a non-executive director, Chairman of the Board and as the chairman or as a member of any other committees of the Board to which you may be appointed from time to time, including, without limitation: preparing for, attending and chairing all meetings of the Board and of the members of the Company (e.g. annual meetings and extraordinary meetings of the Company); preparing for and attending all meetings of any committee to which you may be appointed; attending occasional meetings with the Company’s major shareholders to obtain their views; leading discussions of the Board in relation to corporate strategy; ensuring that all members of the Board receive accurate, timely and clear information concerning the operations and performance of the Company and its Group Companies; preparing agendas for meetings of the Board and the members; assessing the performance of the Board and each individual director of the Company; and reviewing and providing comments in relation to documents or minutes distributed to you following such meetings.

1.5

You agree to make yourself available to attend to your duties for the Company for ten (10) full working days per calendar year at such times and places as are reasonably necessary for the effective and efficient performance of your duties provided that they do not conflict with your other commitments to third parties. For the avoidance of doubt, eight hours shall constitute a full working day (and such hours need not be worked consecutively or on the same calendar day) and time spent travelling shall be counted as working time. The Company shall, after consultation with you, provide you with reasonable notice of the dates of all meetings which you shall be required to attend and shall use its reasonable endeavours to ensure that meetings of any committee to which you are appointed take place immediately before or after Board meetings. For any year during which the agreement is effective for less than 12 months, the number of days of service you are to provide, will be calculated pro rata to the number of months that this agreement is effective in that calendar year.

1.6

You will comply with all lawful and reasonable directions of the Board and all rules and regulations of the Company provided, in each case, they have been notified to you, including without limitation, regulations with respect to confidentiality, dealings in shares and notifications required to be made by a director to the Company or any relevant regulatory body, whether under the company laws of England, the Companies Act, the Articles, applicable United States securities laws, the rules and regulations of the United States Securities and Exchange Commission, or otherwise.

1.7

You shall act in good faith and in the best interests of the Company and exercise all reasonable skill and care in the performance of your duties.

1.8

You confirm that you are aware of your fiduciary duties as a director and your continuing duty to avoid a conflict between your personal and outside interests and the interests of the Company. The Company acknowledges that you have disclosed certain existing interests to it, as referenced in clause 9.1 of this agreement and that, based on the information you have provided to the Company, there appears to be no conflict of interests.

1.9

You consent to the Company holding and processing personal data, including sensitive personal data relating to you ("processing", personal data" and "sensitive personal data" are as defined in the Data Protection Act 1998) to the extent reasonably necessary for legal, personnel, administrative, financial, regulatory, payroll, management and other purposes relating to or ancillary to your appointment. You agree that the Company may disclose such information to other companies within the Group and to third parties in the event that such disclosure is in the Company's view required for the proper conduct of the Company's or the Group's business. This applies to information held, used or disclosed in any medium and whether the use or processing of data is within or outside the European Union

REMUNERATION

2.1

In consideration of you performing your duties for the Company, the Company shall pay you:

2.1.1

non-executive director’s fees at the rate of £82,000 per annum, plus

2.1.2

for every day in excess of 16 days worked, a per diem rate of £1,750.

Such non-executive director's fees shall be paid by equal monthly instalments and shall be subject to deductions for income tax, national insurance contributions and other deductions required by law. The rate of such non-executive director's fees shall be reviewed annually by the Remuneration Committee in its discretion. The Remuneration Committee shall be under no obligation to increase the rate of fees paid to you as a result of any such review but such fees may not be reduced.

2.2

You will not, unless you are notified by the Company in writing at any time, be entitled to participate in the Company’s pension scheme or employee benefits schemes other than stated under clause 3. below

SHARE OPTIONS

3.1

Subject to the conditions contained in this clause 3, the Company will, as soon as practicable following execution of this Agreement, grant you options (“Options”) to acquire a number of ordinary shares par value £0.001 in the capital of the Company (“Shares”) with an aggregate exercise price of £42,000.

3.2.

The Options shall be granted on the basis that:

3.2.1.

The exercise price of each Option will be based upon the mid-market closing price on the business day before the date of grant;

3.2.2

The Option may be exercised 25% on the anniversary of grant and thereafter in 12 equal tranches at the end of the following 12 quarters;

3.2.3

In the event of your death prior to exercise, the Options may be exercised by your validly appointed personal representatives during the period of six months following the date of your death (or such longer period not exceeding 12 months determined by the Board prior to the expiry of that six-month period).

3.3.

The Options may not be transferred (other than to your personal representatives on death) and your interest in them may not be assigned or charged.

FREEDOM TO TAKE UP DUTIES WITH THE COMPANY

You warrant that you will not, by entering into or performing any of your duties for the Company, be in breach of any other agreement, contract or obligation binding on you.

FACILITIES

The Company shall provide you with such secretarial and other facilities as shall be reasonably necessary and agreed between you and the Company in connection with the performance of your duties under this agreement.

DIRECTORS' AND OFFICERS’ LIABILITY INSURANCE

The Company will take out reasonable directors' and officers' liability insurance, which will apply to you for the duration of your appointment, subject to the terms, conditions and limitations of such insurance cover. A copy of the policy can be obtained from the Company Secretary.

EXPENSES

The Company will reimburse you for any reasonable travelling and other expenses you incur in performing your duties for the Company, subject to you providing the Company with receipts, vouchers or other written evidence evidencing such expenditure (in particular, but without limitation, costs incurred on air travel, in accordance with the company’s travel policy, will be fully reimbursed provided that the Company has pre-approved the flights. Costs incurred on Business Class air travel for flights longer than six (6) hours will be fully reimbursed provided that the CEO of the Company (from time to time) has pre-approved the flights.) Any air miles or other loyalty points or benefits which you may obtain as a result of business travel shall be for your personal use.

PROFESSIONAL ADVICE

Occasions may arise when you consider that you need professional advice in connection with the performance of your duties as a non-executive director of the Company and you will be entitled to consult the Company's professional advisers at the Company’s expense to the extent that is reasonably necessary in all the circumstances and that the costs incurred are reasonable and not exceeding £7,500 plus VAT. For expenses exceeding £7,500 plus VAT the agreement from the other non-executive directors or other authorised individuals of the Company is to be received prior to you committing the expenditure.

OUTSIDE INTERESTS

9.1

The Company acknowledges that you are the Chairman of Sareum Holdings plc and Drishti Discoveries Ltd, a non-executive director of MGC Pharmaceuticals Ltd and an executive director of sp² Consulting Ltd. In addition, you have non-fiduciary roles as a Vice Chairman of Canaccord Genuity Limited and a Senior Adviser to Opus Corporate Finance LLP.

9.2

You agree that you will notify the Board in writing of your intention to accept any other employment (not listed in 9.1. above), engagement, appointment, interest or involvement in any (as the context permits) person, firm, company, corporation, business or organisation which competes or conflicts with your appointment (an “Other Interest”). In the event that:

9.2.1

the Board reasonably determines that your acceptance of any such Other Interest would result in a serious conflict of interests; the Board will notify you in writing of this determination within 28 calendar days of receipt of your notification to the Board regarding the Other Interest. Within 7 calendar days of receipt by you of any such notice from the Company, you will confirm to the Board in writing whether you intend to accept the applicable Other Interest.

9.2.2

you reasonably determine that your acceptance of any such Other Interest would result in a serious conflict of interests; you will notify the Board of your view at the same time as you notify the Board of your intention to accept the Other Interest.

You agree that you will, if you decide to accept the applicable Other Interest, submit to the Board (at the same time as you submit the written confirmation regarding your intentions) your written notice of resignation as the Chairman and as a director of the Company, such resignation to take effect after a period of 3 months. It is agreed that neither the Company nor you shall not have any right to damages or compensation in relation to your resignation in these circumstances and that all unvested Options will not vest after the date you cease to be an officer of the Company, except where an Independent Valuation is carried out after the date you cease to be an officer of the Company but in respect of a period during which you were appointed. You hereby irrevocably appoint any other director of the Company from time to time to be your attorney to execute any documents and do anything in your name to effect your resignation as the Chairman and as a director of the Company should you fail to submit your resignation to the Company in accordance with the terms stated in this clause. You agree that a written notification signed by a director of the Company that any instrument, document or act falls within the authority conferred by this clause will be conclusive evidence that it does so; or Notwithstanding any term of this agreement, you may hold (directly or through nominees including your spouse, partner or minor children) by way of bona fide personal investment any units of any authorised unit trust and up to three (3%) percent of the issued shares, debentures or other securities of any company whose shares are listed on a recognised investment exchange or on the alternative investment market.

9.3

During your appointment you shall and will procure that your spouse and minor children comply with:

(a) all applicable rules of law;

(b)

any recognised investment exchange regulations (including the Model Code for Securities Transactions by Directors of Listed Companies issued by the London Stock Exchange plc and any revisions, or amendments of the same or any equivalent regulations issued by any other applicable investment exchange) and

(c)

any policy, code or regulations of the Company or any Group Company notified to you,

relating (in the case of (a) to (c) inclusive) to dealings in shares, debentures or other securities of the Company and any Group Company or relating to any unpublished price sensitive information affecting the securities of the Company, any Group Company or any other company.

10.

CONFIDENTIAL INFORMATION

10.1

During the course of your appointment as a non-executive director of the Company you will have access to and become aware of information which is confidential to the Company and the Group Companies. You undertake that you will not, save in the proper performance of your duties for the Company, use (whether for your own benefit or for the benefit of any other person, firm, company or organisation) or disclose to any person, firm, company or organisation (other than your professional advisers) any of the trade secrets or other confidential information of or relating to: (a) the Company; (b) any Group Company; (c) any customer, client or Prospective Customer (as defined below) of the Company or any Group Company; (d) any person, firm, company or organisation with whom or which the Company is involved in any kind of business venture or partnership; or (e) the business of the Company or any Group Company, which (in the case of each of (a) to (e) inclusive) you received or obtained during your appointment as a non-executive director of the Company. You will likewise use your best endeavours to prevent the unauthorised publication or disclosure of any such trade secrets or confidential information.

10.2

This restriction shall continue to apply after the termination of your appointment for a period of five years, but shall cease to apply to information ordered to be disclosed by a Court or Tribunal of competent jurisdiction or to information which becomes available to the public generally (other than by reason of your breaching this clause).

10.3

For the purposes of this agreement confidential information shall include, but shall not be limited to:

(a)

corporate and marketing strategy and plans and business development plans;

(b)

budgets, management accounts, bank account details and other confidential financial data;

(c)

business, sales and marketing methods, confidential techniques, know how and processes used for the production or development of products and services; services;

(d)

details and specifications of products and services being sold, provided, distributed or developed, including: research and development reports, genetic data, databases, chemical formulae, information relating to pre-clinical or clinical trials, medical records, proprietary vaccines, pharmaceutical compounds and nucleic acid constructs, proprietary bioinformatics, confidential methods and processes, inventions or creations, product specifications, and details of intellectual property solutions or rights relating to products or services;

(e)

details of computer technology; computer programs; software applications and systems; information relating to proprietary hardware or software (including updates); source and object code to proprietary software; confidential algorithms developed or used for such proprietary software;

(f)

details of the salaries, bonuses, commissions and other employment terms applicable to employees;

(g)

The names, addresses and contact details of any customers or Prospective Customers, customer lists in whatever medium this information is stored and the requirements of those customers or the potential requirements of Prospective Customers for any products or services. Without prejudice to the foregoing, personal information provided by visitors to and users of any of its web sites;

(h)

the terms of business with advertisers, customers and suppliers, including any pricing policy adopted and the terms of any partnership, joint venture or other form of commercial co-operation or agreement with any third party;

(i)

software and technical information necessary for the development, maintenance or operation of any websites and the source and object code of each website;

(j)

existing, pending or threatened litigation; and

(k)

Any other information which is the subject of an obligation of confidence owed to a third party, in particular the content of discussions or communications with any Prospective Customers or prospective business partners.

11.

COPYRIGHT, DESIGN RIGHTS AND OTHER RIGHTS

11.1

You will promptly disclose to the Company all works in which copyrights, design rights or database rights (or similar forms of intellectual property protection) may exist which you make or originate either by yourself or jointly with other people during your appointment as the non-executive Chairman of the Company.

11.2

Any copyright work, design or database created by you in the normal course of your appointment or in the course of carrying out duties specifically assigned to you by the Board shall be the property of the Company whether or not the work was made at the direction of the Company or was intended for the Company and the copyright in it and the rights in any design or database shall belong absolutely to the Company throughout all jurisdictions and in all parts of the world, together with all rights of registration, extensions and renewal (where relevant). direction of the Company or was intended for the Company and the copyright in it and the rights in any design or database shall belong absolutely to the Company throughout all jurisdictions and in all parts of the world, together with all rights of registration, extensions and renewal (where relevant).

11.3

To the extent that such copyrights, design rights and database rights (and similar forms of intellectual property protection) are not otherwise vested in the Company, you hereby assign the same to the Company, together with all past and future rights of action relating thereto. In relation to any copyright work, design or database that may be created by you in the future, whether in the normal course of your appointment or in the course of carrying out duties specifically assigned to you by the Board, you hereby assign the copyright, design rights and database rights (and similar forms of intellectual property protection) in the same to the Company with the intention that such copyright, design rights and database rights (and similar forms of intellectual property protection) should forthwith upon completion of the relevant works vest in the Company.

11.4

You recognise and accept that the Company may edit copy, add to, take from, adapt, alter and translate the product of your services in exercising the rights assigned under clause 11.3.

11.5

To the full extent permitted by law, you irrevocably and unconditionally waive any provision of law known as “moral rights” including any moral rights you may otherwise have under sections 77 to 85 inclusive of the Copyright Designs and Patents Act 1988 in relation to the rights referred to at clause 11.2. You give this waiver in favour of the Company and each Group Company, and all successors in title to and licensees of the copyright design right and database right in such works (whether existing or future).

11.6

You agree that you will at the Company's request and expense while you remain a director of the Company and for a period of five (5) years after ceasing to be a director of the Company, execute such further documents or deeds and do all things necessary or reasonably required to confirm and substantiate the rights of the Company under this clause 11.

11.7

You agree that you will not at any time make use of, disclose or exploit the Company's property, trade marks, service marks, documents, materials or information in which the Company or any Group Company owns (wholly or partially) the copyright, design right, database right or semi-conductor topography right (or similar forms of intellectual property protection) for any purpose which has not been authorised by the Company in advance.

11.8

Notwithstanding anything in clauses 10, 11, 12 or 13 of this agreement, you shall own and retain ownership of and may freely use, disclose and exploit any copyright relating to your written business presentations provided that you have first deleted any confidential information relating to the Company or any Group Company from such presentations and that such use, disclosure or exploitation does not infringe or use any of the Company’s trade secrets, trademarks, copyrights or other intellectual property rights.

12.

INVENTIONS

12.1

It shall be part of your normal duties at all times to consider at a strategic level in what manner and by what new methods or devices, products, services, processes, equipment or systems of the Company and each Group Company might be improved and to further the intellectual property interests of the Company. You and the Company agree that, because of the nature of your duties and the particular responsibilities arising from your duties, you have a special obligation to further the interests of the Company.

12.2

You hereby acknowledge and agree that the sole ownership of any invention, discovery, design, improvement or other matter or work whatsoever made or discovered by you from time to time in the course of your appointment and all proprietary rights therein discovered or made by you (whether alone or jointly with others) at any time during your appointment (the “Company Inventions”) shall (subject to any contrary provisions of the Patents Act 1977 and the Copyright Designs and Patents Act 1988 and to any rights of a joint inventor thereof) belong free of charge and exclusively to the Company or as it may direct.

12.3

You shall promptly give to the Board full details of all inventions, discoveries, designs, improvements or other matter or works whatsoever made or discovered by you from time to time during the continuance of your appointment with the Company.

12.4

All worldwide copyright, design rights and database rights in all Company Inventions shall be and remain the property of the Company and the provisions of clause 11 above shall apply in relation to the same.

12.5

You agree that you shall, while you remain a director of the Company and for a period of five (5) years after ceasing to be a director of the Company, at the Company's expense, do all such acts and things and execute such documents (including without limitation making application for letters patent) as the Board may reasonably request in order to vest effectually all Company Inventions, to the extent that the same is the property of the Company or any other Group Company, and any protection as to ownership or use (in any part of the world) of the same, in the Company or any Group Company, or as the Company may direct, and you hereby irrevocably appoint the Company for these purposes to be your attorney in your name and on your behalf to execute and do such acts and things and execute any such documents as set out above.

12.6

You agree that you will not knowingly do or omit to do anything which will or may have the result of imperilling any such protection aforesaid or any application for such protection.

12.7

You agree that you will not at any time make use of, disclose or exploit any Company Invention belonging wholly or partially to the Company or any Group Company for any purpose which has not been authorised by the Company.

12.8

Each of the provisions in this clause 12 is distinct and severable from the others and if at any time one or more of such provisions is or becomes invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions of the clause will not in any way be affected or impaired.

13.

COMPANY PROPERTY

13.1

You may not, save in the proper performance of your duties as a director or with the Company's prior written permission, remove any property belonging to the Company or any Group Company or relating to the affairs of the Company or any Group Company from the Company's or any Group Company's premises, or make any copies of documents or records relating to the Company's or any Group Company's affairs.

13.2

Upon the Company's request at any time and in any event on the termination of your appointment as a non-executive director of the Company, you agree to deliver up to the Company or its authorised representative within two working days or such request from the Company or the termination of your appointment, any and all plans, keys, mobile telephone, security passes, credit cards, customer lists, price lists, equipment, documents, records, papers, computer disks tapes or other computer hardware or software or memory medium or devices (together with all copies of the same), and all property of whatever nature in your possession or under your control which belongs to the Company or any Group Company or relates to its or their business affairs. You will, at the Company's request and without delay, furnish the Company with a written statement confirming that you have complied with this obligation.

14.

TERMINATION

14.1

In the event that the Company terminates your offices of directorship at any time in accordance with the provisions of the Articles (as amended by the Company from time to time) and/or any applicable laws (including where applicable the Laws of the UK and the Companies Act), you agree that you shall have no right to any damages or compensation on or after the date you cease to be a director of the Company if you:

(a)

are guilty of any gross misconduct, gross negligence or dishonesty or act in a manner which is materially adverse to the interests of the Company;

(b)

commit any serious or repeated breach or non-observance of your obligations to the Company (which include an obligation not to breach your statutory, fiduciary or common-law duties);

(c)

become bankrupt, have an interim order made against you under the Insolvency Act 1986 or make any composition or enter into any deed of arrangement with your creditors or the equivalent of any of these under any other jurisdiction;

(d)

become of unsound mind, become a patient under any mental health legislation or be unable due to any accident, illness or injury to undertake your duties for the Company in accordance with the terms of this agreement for a period of more than 6 consecutive months;

(e)

are convicted of a criminal offence (other than a motoring offence for which a non-custodial sentence is imposed on you);

(f)

become disqualified by law or any court of competent jurisdiction from acting as a director of a company; or

(g)

have failed to submit your resignation as the chairman and as a director of the Company when required to do so under the terms agreed in clause 9.2 of this agreement.

14.2

In the event that the Company terminates your office as a director of the Company at any time with immediate effect (other than in accordance with clause 14.1 of this Agreement), the Company shall pay you all director’s fees which would have been due to you for the following twelve (12) months within 14 days of the date of such termination. The parties to this agreement agree that this is a reasonable pre-estimate of your loss.

14.3

You may resign from your office as a director and as Chairman of the Company with immediate effect if the Company:

(a)

is guilty of any gross negligence which affects you or any dishonesty towards or concerning you; or

(b)

Becomes insolvent, makes any composition or enters into any deed of arrangement with its creditors or the equivalent of any of these under any other jurisdiction.

14.4

In the event that you resign from your appointments at any time for any reason which is stated in clauses 14.3(a)–(b) inclusive, the Company shall pay you all director’s fees which would have been due to you for the following twelve (12) months within 14 days of the date of such termination. The parties to this agreement agree that this is a reasonable pre-estimate of your loss.

14.5

In the event that you are unable due to any accident, illness or injury to undertake your duties for the Company in accordance with the terms of this agreement for a period of more than 6 consecutive months you may thereafter resign from your office as a director of the Company at any time and without the Company having any right to damages or compensation.

14.6

In the event that you wish to resign your office as a director of the Company for a reason other than those stated in clause 9.2, clause 14.3(a)-(b) inclusive or clause 14.5 you agree to give the Company not less than twelve (12) months’ written notice of resignation.

14.7

Notwithstanding any other term of this agreement, you agree that the Company may terminate your appointment as a director under this agreement at any time after the Initial Fixed Term by giving to you not less than three (3) months’ written notice of termination expiring on or after the end of the Initial Fixed Term. In the event that notice is given to you by the Company, you agree that, prior to the expiry of the notice period, you will submit to the Board your written resignation as the Chairman and as a director of the Company, such resignation to take effect on the expiry of the said notice period. You hereby irrevocably appoint any other director of the Company from time to time to be your attorney to execute any documents and do anything in your name to effect your resignation as the Chairman and as a director of the Company should you fail to resign on or before the date of expiry of such period of notice of termination given to you by the Company. You agree that a written notification signed by a director of the Company that any instrument, document or act falls within the authority conferred by this clause will be conclusive evidence that it does so.

14.8

Upon the termination of your appointment as a non-executive director of the Company for whatever reason or at the request of the Board, you shall resign promptly (with such resignation taking immediate effect) from all other directorships held by you in any Group Company. You hereby irrevocably appoint the Company to be your attorney to execute any documents and does anything in your name to effect your resignation as a director of any Group Company should you fail to resign promptly following a request from the Company to do so in accordance with this clause. A written notification signed by a director of the Company that any instrument, document or act falls within the authority conferred by this clause will be conclusive evidence that it does so.

15.

DEFINITIONS

15.1

Any reference in this agreement to:

15.2

any Act or delegated legislation includes any statutory modification or re-enactment of it or the provision referred to;

15.3

“the Articles” means the Articles of Association of the Company as amended from time to time;

15.4

“the Board” shall mean the Board of Directors of the Company from time to time or any person or any committee of the Board duly appointed by it;

15.5

“The Companies Act” means the Companies Act 2006;

15.6

“Group Company” means a company which from time to time is a subsidiary or a holding company of the Company or a subsidiary of such holding company (where the terms “subsidiary” and “holding company” have the meanings attributed to them in section 1159 of the Companies Act);

15.7

“Prospective Customer” means any person with whom the Company or any Group Company is in negotiations in relation to the sale or supply of goods and/or services by the Company or any Group Company to such person or to whom the Company or any Group Company has submitted a tender relating to such sale or supply arrangement; and

15.8

“Effective Date” means the date on which the appointment as non executive director and Chairman becomes effective.

16.

JURISDICTION/LANGUAGE OF THE CONTRACT

16.1

This agreement is governed by and construed in accordance with the laws of England and Wales and the parties submit to the non-exclusive jurisdiction of the English courts.

IN WITNESS WHEREOF this agreement has been executed and delivered as a deed on the date set out above.

EXECUTED and DELIVERED as a DEED
by MIDATECH PHARMA PLC

Acting by:	/s/ Stephen Stamp….………………………………
	Director

	…/s/ Rolf Stahel.………………………………
	Director

EXECUTED and DELIVERED as a DEED

by STEPHEN B. PARKER:

…/s/ Stephen B. Parker………………………………

in the presence of:

Signature of witness	…/s/ Doris Campbell………………………………

Print name of witness	…Doris Campbell…..……………………….

Print address of witness	…………………………………

	…………………………………

Print occupation of witness	…………………………………

Exhibit 99.1

20 June 2022

Midatech Pharma PLC

("Midatech" or the "Company")

Directorate Change

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the appointment of Dr Stephen Parker as a Director of the Company and Non-Executive Chairman of the Board with immediate effect.

Stephen Parker has over 30 years’ experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp² Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.

Dr Parker is taking over from Rolf Stahel, who has resigned as a Director of the Company and stepped down as Chairman in line with his proposed retirement, previously announced on 10 June 2022.

Additional Information

The following information is disclosed pursuant to Schedule Two paragraph (g)of the AIM Rules for Companies in relation to Dr Stephen Barry Parker, aged 63:

Current Directorships and Partnerships	Previous Directorships and Partnerships(past 5 years
Sareum Holdings Plc	Silence Therapeutics Plc
Sareum Limited	Liverpool Chirochem Limited
sp² Consulting Limited	Albucasis Limited
sp² Asset Management Ltd
MGC Pharmaceuticals Limited
Drishti Discoveries Ltd.
Eternans Ltd

Dr Parker was formerly a director of Celtic Pharma Development UK Plc, Xenova Group Limited and Xenova Limited, each of which were subsidiaries of Celtic Pharma GP Limited and were placed into creditors voluntary liquidation in April 2014.

As of the date of this announcement, Dr Parker holds no ordinary shares or options in the Company.

Save as disclosed above, there are no additional disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules for Companies.

For more information, please contact:

Midatech Pharma PLC
Stephen Parker, Chairman Stephen Stamp, CEO, CFO
Tel: +44 (0)29 20480 180
www.midatechpharma.com

Strand Hanson Limited (Nominated and Financial Adviser)

James Dance / Matthew Chandler / Rob Patrick

Tel: +44 (0)20 7409 3494

Turner Pope Investments (TPI) Ltd (Joint Broker)

Andrew Thacker / James Pope

Tel: +44 (0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Alyssa Factor

Tel: +1 (860) 573 9637

Email: afactor@edisongroup.com

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies, to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company’s technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech’s technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information, please visit www.midatechpharma.com

Exhibit 99.2

20 June 2021

Midatech Pharma PLC

(“Midatech” or the “Company”)

Result of 2022 Annual General Meeting

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its Annual General Meeting (AGM) held at 2.00pm today all resolutions put to the meeting were duly passed.

For more information, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)29 20480 180

www.midatechpharma.com

Strand Hanson Limited (Nominated and Financial Adviser)

James Dance / Matthew Chandler / Rob Patrick

Tel: +44 (0)20 7409 3494

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker / James Pope

Tel: +44 (0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Alyssa Factor

Tel: +1 (860) 573 9637

Email: afactor@edisongroup.com

About Midatech Pharma PLC

Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

Exhibit 99.3

MTX110 Development for the Treatment of Glioma Released : 21 Jun 2022 07:00 RNS Number : 5470P Midatech Pharma PLC 21 June 2022 21 June 2022 Midatech Pharma PLC ("Midatech" or the "Company") Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following the submission of an application to the European Medicines Agency ("EMA"), its development programme of MTX110 for the treatment of glioma has been granted Orphan Medicinal Product designation by the agency. Midatech has been developing MTX110 for the treatment of recurrent glioblastoma ("rGBM") in adult patients and diffuse intrinsic pontine glioma ("DIPG") and medulloblastoma in paediatric patients. Orphan designation is granted by the EMA to medicines that meet pre-specified criteria, including treatment of a lifethreatening condition and prevalence of no more than 5 in 10,000 in the EU. The designation is intended to offer a range of incentives that facilitate development of the medicine, such as protocol development assistance, reduction in fees and market exclusivity upon successful approval of the drug. Commenting, Dmitry Zamoryakhin, CSO of Midatech, said: "Both rGBM and DIPG are devastating and incurable cancers marked by short survival rates and universal recurrence. Receiving Orphan designation for MTX110 is an important milestone for the development of the drug, as it demonstrates the need for novel and effective treatment options for these fatal diseases and highlights a potential benefit that the development of MTX110 might bring to patients." About MTX110 MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan- HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559). For more information, please contact: Midatech Pharma PLC Dmitry Zamoryakhin, CSO Tel: +44 (0)29 20480 180 www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser) James Dance / Matthew Chandler / Rob Patrick Tel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Limited (Joint Broker) Andrew Thacker / James Pope (Corporate Broking) Tel: +44 (0)20 3657 0050 IFC Advisory Limited (Financial PR and UK Investor Relations) Tim Metcalfe / Graham Herring Tel: +44 (0)20 3934 6630 Email: midatech@investor-focus.co.uk Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: afactor@edisongroup.com About Midatech Pharma PLC Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform: · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). · MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. · MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease. The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCQBLFLLQLEBBK